Vagal Atrial Fibrillation
Transcription
Vagal Atrial Fibrillation
Review Acta Cardiol Sin 2007;23:1-12 Vagal Atrial Fibrillation Yung-Hsin Yeh,1,2,4 Kristina Lemola1,2 and Stanley Nattel1,2,3 The autonomic nerve system plays an important role in atrial fibrillation (AF). Vagal AF refers AF (generally paroxysmal) arising in contexts of enhanced parasympathetic tone. Heterogeneity of refractoriness and action potential abbreviation resulting from spatially variable parasympathetic enhancement of the acetylcholinedependent K+-current (IKACh) underlie vagal AF. Adrenergic influences may also contribute to the occurrence of vagal AF. Cholinergic stimulation may enhance ectopic firing from pulmonary vein cardiomyocytes, which potentially contribute to the occurrence of vagal AF. On the other hand, underlying heart disease modulates cholinergic regulation of atrial myocytes. Careful history taking in AF patients is important for vagal AF management. Vagal denervation may play a role in the efficacy of ablation procedures, but the results are conflicting. Specific IKACh channel blockers may become the treatment of choice in the future. Key Words: Vagal atrial fibrillation · Acetylcholine · Muscarinic receptor · Pulmonary vein · Vagal denervation INTRODUCTION administration can induce AF without electrical stimulation of the atrium. In this article we will review the effects of ACh on ion channels in atrial myocytes and on the electrophysiology of atrial tissue, as well as the electrophysiological mechanisms of vagal AF. Finally, we will discuss clinical relevance and potential treatment of vagal AF. The autonomic nervous system is known to play an important role in the occurrence of atrial fibrillation (AF). 1 Several clinical observations suggest that enhanced parasympathetic tone is involved in some cases of paroxysmal AF, clinically referred to as “vagal AF”.2,3 Coumel was the first physician to use the terms vagal and adrenergic AF in his studies on autonomic tone and AF.1 The effects of parasympathetic stimulation on cardiomyocytes are mainly through changes in ion channel function in response to the activation of muscarinic acetylcholine receptors (mAChRs) following release of the neurotransmitter acetylcholine (ACh). In experimental animal models, both vagal stimulation and acetylcholine Cellular ionic-current effects of acetylcholine in atrium The cardiac effects of parasympathetic stimulation are mediated through the vagus nerve. Release of ACh activates mAChRs. The parasympathetic system exerts important physiological influences over pacemaker activity, atrioventricular conduction, action potential duration (APD) and contractile force. In mammals, the M2 receptor is the predominant mAChR subtype expressed in heart.4 The coupling of M2AChR activation to most changes in cardiac ion channels is via the pertussis toxin-sensitive G protein (Gi/o). Gi activation inhibits adenylyl cyclase. Furthermore, M2AChRs can couple to certain K+ channels, referred as G-protein regulated inward-rectifier K+ channels (GIRK), and can influence Ca2+ channels, the “funny” current (If) involved in pace- Received: November 22, 2006 Accepted: December 14, 2006 1Department of Medicine and Research Center, Montreal Heart Institute, Quebec, Canada; 2Department of Medicine, University of Montreal, Quebec, Canada; 3Department of Pharmacology McGill University, Quebec, Canada. 4First Cardiovascular Division, Chang Gung Memorial Hospital, Chang Gung University, Tao-Yuan, Taiwan. Address correspondence and reprint requests to: Dr. Stanley Nattel, 5000 Belanger Street East, Montréal, Québec, H1T 1C8, Canada. Tel: (514)-376-3330 ext. 3990; Fax: (514)-376-1355; E-mail: stanley. Nattel@icm-mhi.org 1 Acta Cardiol Sin 2007;23:1-12 Yung-Hsin Yeh et al. pathetic effects on the heart. Cardiac GIRK channels are composed of two homologous proteins: GIRK1 and GIRK4 (Kir3.1 and 3.4). 15 In mammals, I KACh is found in the SAN, atria, AVN and Purkinje fibers. 16 When acetylcholine is applied to atrial myocytes, heterotrimeric Gi/o-proteins (composed of an a, b and g subunit) coupled to mAChRs dissociate into their constituent Gai/o and Gbg dimer subunits. Dissociated Gai/o and Gbg subunits are able to modulate physiological actions by interacting with numerous effectors, including protein kinases, phospholipases, phosphodiesterases and ion channels. Gbg is the primary activator of GIRK channels via a membrane delimited pathway. 17 In SAN, I KACh results in membrane hyperpolarization and slowing of pacemaker activity. In atrial myocytes, I KACh causes atrial repolarization and is the main current that ACh activates to shorten APD, which facilitates reentry and tachyarrhythmia. Regulation of L-type calcium current ICa.L Muscarinic activation suppresses ICa,L.18,19 This suppressive effect could be via inhibition of adenyly cyclase, thereby decreasing cAMP concentrations, or via cGMP/ PKG-dependent activation of okadaic acid-sensitive protein phosphatase.20,21 This decrease in ICa,L may contribute to the APD shortening by cholinergic stimulation. Effects on other ion currents In guinea pig cardiomyocytes, ACh alone has no effect on delayed rectifier K+ currents (IK), but the increase in IK by isoproterenol can be antagonized by ACh via reduction of intracellular cAMP.22 INa may be enhanced by muscarinic stimulation23 whereas Cl- current activated by b-adrenergic agonists are suppressed by muscarinic stimulation.24 The physiological roles of these responses in human hearts are still unclear. Effects on gap junction Muscarinic activation can also affect gap junction function in the heart. Takens-Kwak et al.9 showed that muscarinic activation in neonatal rat cardiomyocytes reduces the intercellular current. Gap junction conductance in cultured neonatal rat cardiomyocytes is also decreased by carbachol in a cGMP-dependent manner.8,10 These results suggest that muscarinic activation inhibits gap junction communication, which could decrease conduction velocity in atrium, which might facilitate reentry and lead to arrhythmia. making, phospholipase A2, phospholipase D and tyrosine kinase. 5-7 Some studies also suggest that the cyclic guanosine monophosphate ( cGMP) signaling pathway is involved in muscarinic activation.8-10 Activation of mAChRs in the heart results in (1) hyperpolarization and slowed spontaneous depolarization in sinoatrial node (SAN), (2) shortened APD and reduced contractile force in atrium and (3) decreased conduction velocity in the atrioventricular node (AVN). The effects on cardiac electrophysiology are mainly through regulation of membrane ion channels and possibly gap junctions. Figure 1 shows an overview of mAChR regulation of cardiac ion channels. Regulation of pacemaker current If ACh decreases I f and shifts its activation to more negative potentials, thus slowing pacemaker activity in SAN.11,12 If is a directly cAMP-sensitive current.13 The ACh-induced decrease in If is mainly via mAChRs and Gi/o protein, resulting in inhibition of adenylyl cyclase and decreased cAMP production. In addition, there is an alternative pathway by which mAChR activation can inhibit If via cAMP-independent signaling, but this may be of lesser importance.14 Regulation of IKACh I KACh is an inwardly-rectified K + current carried by GIRK (Kir3) channel subunits activated by acetylcholine or other muscarinic agonists. I KACh activation is believed to be the principle mediator of parasym- Figure 1. Overview of signaling pathways responsible for M2AChR regulation of cardiac ion channels. ACh, acetylcholine; M2, muscarinic acetylcholine receptor subtype 2; GIRK, G-protein regulated inwardrectifier K+ channels; IKACh, acetylcholine-sensitive K+ current; If, pacemaker current; ICa,L, L-type Ca2+ current; PKA, protein kinase A; PKG, protein kinase G. Acta Cardiol Sin 2007;23:1-12 2 Vagal Atrial Fibrillation Tissue effects of cholinergic stimulation Cholinergic stimulation abbreviates APD and ERP, mainly through the activation of I KACh . Experimental studies also show that vagal stimulation increases the spatial dispersion in atrial refractoriness,25-28 as well as in APD. Both absolute APD/ERP shortening and increased APD/ERP heterogeneity facilitate reentry and tachyarrhythmia. Liu et al.27 showed that vagal stimulation increases the variability in atrial refractoriness, as indicated by the standard deviation of ERP at different atrial sites and of activation frequency during AF. Although sympathetic stimulation also decreases atrial ERP, it has no significant effect on these indexes of ERP heterogeneity.27 Perhaps because of its lack of effect on spatial ERP dispersion, sympathetic stimulation was much less effective than vagal stimulation in promoting AF. In another animal study in which AF was induced by vagal stimulation,29 flecainide doses that terminated AF significantly reduced refractoriness heterogeneity during nerve stimulation, to the same range under control conditions without nerve stimulation. These observations suggest that increased heterogeneity may be a very important atrial proarrhythmic vagal mechanism. This idea is compatible with both experimental and computer models of AF which indicate that heterogeneity in refractoriness is an important determinant of AF occurrence.30-32 Potential mechanisms for the increased spatial heterogeneity in refractoriness induced by vagal stimulation includes inhomogeneous nerve innervation33,34 and varying IKACh densities due to heterogeneous distribution of mAChRs and/or GIRK channels over the atria.34-37 Labeling for the high affinity choline transporter, an indicator of cholinergic nerve fibers, is distributed heterogeneously over the atria.34 These fibers are abundant in the sinus and atrioventricular nodes, interatrial septum, and much of the right atrium (RA), but less abundant in the left atrium (LA). Lomax et al.35 also showed that in mouse atria IKACh current density is significantly higher in SA node myocytes than either RA or LA myocytes and I KACh is significantly larger in RA than in LA myocytes. In sheep, Sarmast et al 37 showed a greater abundance of GIRK1/4 mRNA level and IKACh densities in LA than in RA, which may account for more AChinduced rotors observed by optical mapping in LA than in RA. Huang et al. 36 showed that the densities of mAChRs and IKACh measured by Western blot and patch clamp respectively are higher in LA, RA appendage and LA free wall of dogs than in RA free wall, PVs and superior vena cava. Administration of amiodarone eliminates the difference in IKACh densities between LA and RA, but IKACh is still higher in LA and RA appendage. They suggested that decreased dispersion of IKACh densities may be a potential mechanism for amiodarone efficacy in AF. Mapping studies show that spontaneous premature atrial premature depolarizations precede spontaneous AF induced by vagal stimulation.38 The mechanism of thess spontaneous atrial depolarizations that trigger vagal AF was proposed to be local microreentry.32,38,39 Computer simulation suggests that vagal AF is maintained by single or a small number of reentry sources with fibrillatory conduction.32,39 Kneller et al.32 showed that cholinergic stimulation stabilizes the primary spiral wave generator and vagal-mediated refractoriness heterogeneity results in wavefront disorganization and breakup. These results are compatible with experimental mapping studies which show that vagal stimulation greatly increases the generation of atrial extrasystoles initiating AF.38,40,41 In a study in which AF was induced by ACh perfusion in isolated canine RA preparations,41 activation sequence mapping revealed multifocal atrial premature depolarizations and regions of functional block during AF. In another study, Sharifov et al.38 stimulated vagus nerve in open chest dogs to induce AF and showed that vagal-mediated focal ectopic atrial premature depolarizations are widely distributed over the atria. The occurrence of atrial tachyarrhythmia events increased proportionally with stimulation intensity. In most cases of sustained AF, a single leading and stable source of reentry circuit was established after second to third beat or after interaction among unstable sources. Both animal and computer simulation models suggest that spiral wave reentry42 underlies vagal AF. IKACh is essential in the generation of vagal AF. In Kneller’s32 study the authors suggested that IKACh is a determinant of frequency and stability during vagal AF. Kovoor et al.43 studied an IKACh-deficient (GIRK4 knockout) mouse model and found that AF can’t be induced in knockout mice lacking IKACh, indicating that activation of IKACh is required for cholinergic AF. AF was induced in the presence of carbachol by burst pacing in 10/14 3 Acta Cardiol Sin 2007;23:1-12 Yung-Hsin Yeh et al. wild type mice, and lasted for a mean of 5.7 ± 11 min, but AF could not be induced in the absence of carbachol. In knockout mice, atrial arrhythmia could not be induced with or without the use of carbachol. Interactions between cholinergic and adrenergic stimulation Both cholinergic and adrenergic stimulation can promote the occurrence of AF, although adrenergic stimulation is much less effective than cholinergic stimulation.27,44 Interaction between adrenergic and cholinergic tone may play an important role in initiating and perpetuating AF:44,45 simultaneous adrenergic stimulation has been shown to facilitate the induction of ACh-mediated AF.45 Sharifov et al.44 showed that catecholamine can induce AF (about 20% of the time) in open chest dogs, and atropine completely prevents catecholamine-mediated AF, indicating an important role of cholinergic tone in these AF episodes. ACh induced AF in all dogs and b-adrenergic blockade didn’t prevent ACh-induced AF, but increased the threshold ACh concentration for AF induction. Catecholamine administration decreased the threshold of ACh concentration for AF induction and increased AF duration. These results suggest that both cholinergic and adrenergic stimulation can contribute to AF induction during the activation of both systems, and cholinergic stimulation plays a more potent role in AF than adrenergic stimulation in this model. In a human study, Bettoni et al.46 showed that the occurrence of paroxysmal AF greatly depends on fluctuations in autonomic tone. Using heart rate variability (HRV) analysis method, they showed an increase in high-frequency components (which suggest increased cholinergic tone) as well as a progressive increase in low-frequency components (which suggest increased adrenergic tone) at least 20 min before AF. The low/high frequency ratio showed a linear increase until 10 min before AF onset, followed by a sharp decrease immediately before AF. They also showed no difference in HRV between patients with and without underlying heart disease. These findings suggest that both components of the autonomic system are involved in the initiation of paroxysmal AF, with an initial increase in adrenergic tone followed by a shift to vagal predominance. Cholinergic effects on PV myocyte arrhythmogenesis Pulmonary veins (PVs) are known to be important in Acta Cardiol Sin 2007;23:1-12 initiating and maintaining AF.47 Radiofrequency catheter ablation in and around PVs is most effective in curing AF among patients without structural heart disease. In dogs PVs have been shown to exert rapid firing of ectopic foci and triggered AF-mediated by triggered activity or abnormal automaticity,48 although this has not been a universl finding.49 Since both vagal AF and PV-related AF often occur in patients without structural heart disease,1 it is natural to investigate the role of cholinergic effects on PVs arrhythmogenesis. Recent studies showed that the autonomic nervous system plays important role in initiating PV firing and paroxysmal AF.50-55 Schauerte et al.50 performed high-frequency electrical stimulation in the PVs in dogs, leading to local ERP shortening and occurrence of AF. The response to high-frequency electrical stimulation was completely abolished by atropine, but only blunted by b-adrenergic blockers. Scherlag et al.54 showed in an open chest canine model that when the autonomic ganglion located at the base of the PVs was stimulated, producing a response of reduction in heart rate, fewer atrial premature depolarizations were required to induce AF than in control conditions without ganglionic stimulation. The authors suggested that autonomic ganglion stimulation, which led to vagal responses in this experiment, facilitates the conversion of PV firing into AF. In a human study, Zimmermann et al.55 showed that in patients with focal ectopic firing from the PVs, episodes of AF were associated with variations in autonomic tone, with a significant shift toward vagal predominance before AF onset. Takahashi et al. 53 further showed in humans that vagal excitation was associated with shortening of fibrillatory cycle length in the PVs and facilitated AF. These studies suggest that the PVs are susceptible to enhanced vagal tone in triggering AF. Triggered activity has been proposed to be the mechanism of PV arrhythmogenesis resulting from enhanced parasympathetic tone. Patterson et al.51,56 provided data suggesting that enhanced sodium-calcium exchange activity initiated by the calcium transient is responsible for focal firing from the PVs during field stimulation. With the application of ACh, abbreviated APs and early afterdepolarizations (EADs) were induced in superfused canine PV preparations. With co-application of ACh and norepinephrine, tachycardia-pause triggered rapid firing within the PV sleeve. The authors proposed that in the 4 Vagal Atrial Fibrillation PVs, the abbreviation of APs by ACh enhanced calcium transients, promoting EAD formation and tachyarrhythmia. Other findings suggest that vagal enhancement can suppress paroxysmal AF originating from the PVs.57,58 Tai et al.57 showed that in patients with focal AF originating from the PVs, the frequency of ectopic activity as well as AF bursts from the PVs were significantly reduced after intravenous phenylephrine infusion, which causes vagal enhancement and sympathetic withdrawal. The authors proposed that reduced automaticity by vagal tone may decrease focal firing from PVs. More studies are needed to explain the role of autonomic function in PV-related AF. Figure 2 shows an overview of proposed electrophysiological mechanisms by which enhanced parasympathetic tone favours the induction of AF. Vagal remodeling and roles of mAChRs and GIRK channels in AF Although most vagal AF occurs in patients without structural heart disease,2 the parasympathetic system and its effectors also plays a role in AF patients with underlying heart disease. Parasympathetic tone is likely to be remodeled in AF. Blaauw et al.59 showed that in goats after 24-hour rapid atrial pacing, there was a significant increase in HRV, suggesting an increase in vagal tone. During recovery from atrial ERP shortening, higher vagal tone was associated with shorter atrial ERP and attenuated recovery. Several studies in human and animal models also showed that both mAChRs and GIRK channels are remodeled in AF. In a canine model of AF induced by heart failure and in humans with AF, IKACh is downregulated, 60,61 and protein or mRNA expression levels of both GIRK1/4 and M2AChRs are reduced.60-62 On the other hand, the activity of acetylcholinesterase, the enzyme that hydrolyzes ACh at cholinergic neuroeffector junctions, is reduced in chronic AF,63 which may partially compensate for the reduced IKACh density by increasing ACh cncentrations in the synaptic cleft. Ehrlich et al showed that a consitutively-active IKACh (measurable in the absence of ACh) is present in left atrium, particularly in PVs, and is upregulated by atrial tachycardia remodeling.64 Dobrev et al.65 showed that in patients with chronic AF, IKACh is also upregulated. The increased constitutively active IKACh could be explained by higher channel open probability in chronic AF than in Figure 2. Diagram of proposed electrophysiological mechanisms contributing to vagal AF. AP, action potential; EAD, early afterdepolarization. sinus rhythm (5.4 ± 0.7% versus 0.13 ± 0.05%). In canine it was also shown that atrial tachycardia remodeling increased constitutively active IKACh, and a highly selective GIRK channel antagonist, tertiapin-Q, increased APD and suppressed atrial tachyarrhythmias in atrial tachycardia-remodeled preparations.66 These results suggest that GIRK channels are activated in AF even in the absence of cholinergic stimulation and that this contributes to AF-related APD shortening and AF arrhythmogenesis. Since atrial tachyarrhytmia could be terminated by tertiapin-Q, GIRK channels are a potentially interesting target in AF. Wallukat et al.67 showed that autoantibodies directed against M2AChRs (M2AAB) are present in about 40% of patients with cardiomyopathy of various etiology. Baba et al.68 also showed that M2AAB is detected in 40% of patients with dilated cardiomyopathy and in 23% of AF patients without structural heart disease, versus 8% in healthy control. Purified M 2 AAB obtained from both lone AF and dilated cardiomyopathy patients were injected into chick embryos, resulting in negative chronotropic effects and induced supraventricular arrhythmias. This study suggests that M2AAB could play a proarrhythmic role in AF patients with or without structural heart disease via activation of mAChRs. Clinical relevance Clinically, vagal AF is considered if paroxysmal AF episodes occur at rest, after meals or during sleep and 5 Acta Cardiol Sin 2007;23:1-12 Yung-Hsin Yeh et al. et al.77 showed that among patients with PSVT, higher baroreflex sensitivity (BRS), which implies higher vagal reactivity, and greater atrial ERP dispersion during episodes of PSVT are seen in patients with PSVT associated with paroxysmal AF. This observation suggests that higher vagal reflex tone contributes to the genesis of paroxysmal AF in patients with PSVT. However, evidence regarding the pathophysiological mechanisms underlying vagal AF is not consistent. van den Berg et al.69 showed that vagal AF is not caused by increased vagal reactivity. They grouped vagal AF and non-vagal AF among paroxysmal AF patients by clinical criteria. They showed that either a battery of autonomic tests (with use of the Finapress system) or BRS is not significantly different between vagal AF and non-vagal AF patients. Furthermore, vagal reactivity among paroxysmal AF patients was below the normal range.78 The authors suggested that either increased susceptibility of the heart to vagal influences or increased vagal tone could potentially play important roles in vagal AF. More studies are needed. stop in the morning or with exercise (Table 1). Vagal AF usually occurs in young patients with ages between 30 and 50, more frequently in men and without structural heart disease. The ECG commonly shows flutter alternating with fibrillation. In contrast, adrenergic AF usually occurs in the presence of structural heart disease. Holter monitoring may show sinus bradycardia before the onset of AF and a slow ventricular response during AF.1,69 However, manifestations of vagal and adrenergic AF may coexist in the same patient, and the clinical pattern may change over time. Characterization and quantification of autonomic changes and evaluation of vagal AF in humans are difficult to refine. Analysis of heart rate variability (HRV) is a noninvasive and useful method to evaluate the balance between sympathetic and parasympathetic tone.3,70 An increase of low-frequency/high-frequency (LF/HF) ratio means an enhancement of sympathetic tone whereas a decreased ratio means an enhancement of parasympathetic tone. However, this approach is over-simplified and may not always accurately reflect autonomic function. Some studies have shown that paroxysmal AF occurring during sleep are preceded by an increase in high-frequency components, suggesting increased vagal activity preceding AF.71-73 However, one group showed data suggesting that sympathetic tone is increased before AF onset during sleep.74 Another group showed that both LF and HF components are increased before AF onset, with no change in LF/HF ratio.75 These findings may be due to the presence of autonomic fluctuation before the onset of paroxysmal AF.46 Different patient groups may have contributed to discrepancies. Concurrent enhancement of sympathetic tone may play a role in some cases of vagal AF. Paroxysmal AF tends to co-exist in patients with paroxysmal supraventricular tachycardia (PSVT).76 Chen Therapeutic Implications Pharmacological treatment Management of AF should be directed according to the condition and the underlying disease.45 Studies available so far indicate that no clear advantage exists between rhythm control and rate control in AF.79,80 Only anecdotal data are available regarding the pharmacological rhythm control of vagal AF.1,81,82 van den Berg et al. reported a case of typical vagal AF, presenting episodes predominantly at rest, during sleep, and after physical activity.81 Medication with digoxin, verapamil, sotalol, and flecainide was ineffective. The patient was treated successfully with disopyramide, which has anticholinergic properties. HRV analysis showed a decrease in Table 1. Characteristics of vagal-mediated and adrenergic-mediated AF Vagal-meduated AF More common Predominence in man, age between 30 and 50 years Patients without heart disease (long AF) Preferentially noctural, during rest, after eating or drinking Preceded by bradycardia Lower ventricular response rate during AF Aggravation by b-blocker and/or digoxin Acta Cardiol Sin 2007;23:1-12 Adrenergic-mediated AF Less common No particular predominence Often in patients with identified heart disease During daytime or diurnal, provoked by exercise or emotional stress Preceded by tachycardia Higher ventricular response rate during AF Benefit from b-blocker and/or digoxin 6 Vagal Atrial Fibrillation prevention in both animal models and in patients during cardiac surgery. Chiou et al.87,88 showed that most vagal fibers travel through a fat pad located between aortic root and superior vena cava, then project onto two fat pads over the heart: one at the junction between inferior vena cava and LA, the other at the junction of right PV and RA. They showed that radiofrequency catheter ablation of these fat pads eliminates HRV and BRS. Some studies suggest that it may not be necessary to ablate all three pads to suppress AF induced by vagal stimulation. 28,89 However, the results of partial vagal denervation are conflicting. One study showed that ventral cardiac denervation reduces the occurrence of AF after coronary artery bypass grafting, 90 but another group showed that a similar strategy to prevent post-cardiac surgical AF is ineffective.91 Cummings et al.92 showed that removal of a fat pad located between the pulmonary artery and aorta during cardiac surgery prevented sinus bradycardia induced by vagal nerve stimulation, suggesting the presence of vagal fibers. Paradoxically, removal of this fat pad increased the incidence of postoperative AF. Hirose et al.93 showed that partial vagal denervation facilitates rather than preventing vagallymediated AF. The likely explanation is that partial vagal denervation worsens autonomic imbalance, as well as parasympathetic inhomogeneities. Nerve regeneration may attenuate the long-term effects of vagal denervation. Oh et al.94 showed l that epicardial radiofrequency ablation over fat pads in dogs effectively reduces the inducibility of vagally-mediated AF, but 4 weeks later the effect is lost. Selective GIRK channel antagonists Cardiac-selective specific GIRK channel antagonists could be useful in the treatment of AF. In GIRK4knockout mice,43 vagal AF is prevented without favoring ventricular arrhythmias or affecting AVN function. Therefore, GIRK blockers are potentially therapeutic without adverse effects on ventricular arrhythmia or conduction. However, the sinus rate might be accelerated by GIRK antagonists. In a canine study, Hashimoto et al.95 showed that tertiapin-Q, a specific GIRK channel antagonist, prolongs atrial ERP and terminates AF induced by vagal stimulation, without affecting ventricular repolarization. Cha et al. 66 showed that a GIRK channel antagonist is effective in an atrial tachyrdia-induced AF model. high-frequency components after successful treatment. Digoxin or b-blockers are generally not beneficial and can even be detrimental to vagal AF, although they are commonly used in AF with structural heart disease. Class I antiarrhythmic drugs with vagolytic effects are theoretically effective in treating vagal AF. Propafenone is not very effective because of its b-blocking properties. Coumel2,82 recommended flecainide, quinidine, and disopyramide in treating vagal AF (in decreasing order, respectively). PV isolation and/or vagal denervation PVs are well-known to provide a focal origin of AF in many patients, and PV ablation is effective in curing paroxysmal AF.47 Oral et al.58 showed that PV isolation is less effective in patients with vagal AF than patients with adrenergic or mixed form. Razavi et al.83 showed that ablation around the PV-LA junction decreases the degree of atrial ERP shortening and vulnerability to AF induced by vagal stimulation. Their results suggested that the ganglion plexus around PV-LA junction contributed to cholinergic innervation in the atria and ablating this region of ganglion plexi can effectively diminish the atrial response to vagal stimulation. PVs isolation plus vagal denervation can be effective in treating vagal AF.84 Pappone et al.84 showed that in patients with paroxysmal AF, after circumferential PV ablation, adjunctive vagal denervation significantly reduced the recurrence of AF at a 12-month follow-up (99% versus 85% in patients without adjunctive vagal denervatioin). Ablating around the entrance of PVs achieved vagal denervation at areas corresponding to areas at which slowing of sinus rhythm or slowing of ventricular response during AF was obtained during radiofrequency ablation. Scherlag et al.85 also reported the effects of PV isolation plus ganglion plexus ablation in AF patients. The ganglionic plexi were also identified around the entrance of PVs. Prior to PVs isolation, ganglion plexus ablation alone abolished focal firing from PVs in 95% of cases. These findings are compatible with experimental studies showing that enhanced parasympathetic tone facilitates focal firing from PVs and that vagal denervation abolishes this effect. Recently, Tan et al.86 showed that adrenergic and cholinergic nerves are at highest densities within 5 mm of the PV-LA junction and that both are situated close to each other and can even be intermixed. Vagal denervation alone has been evaluated for AF 7 Acta Cardiol Sin 2007;23:1-12 Yung-Hsin Yeh et al. CONCLUSION 11. The autonomic nerve system, and particularly the vagal copmponent, plays an important role in AF. Clinical observations show that enhanced parasympathetic tone contributes to some cases of paroxysmal AF, clinically referred to as vagal AF. The electrophysiological mechanisms of vagal AF mainly comprises atrial APD/ ERP shortening and increased dispersion of atrial refractoriness via activation of IKACh. Cholinergic stimulation may also enhances focal firing from PVs. Interactions between vagal and adrenergic tone may also playa role in AF. Vagal denervation likely decreases the occurrence of some AF but the long-term efficacy of vagal denervation is questionable. Careful history-taking is important for accurate diagnosis and appropriate pharmacological treatment of vagal AF. Selective GIRK blockers could potentially become the treatment of choice for vagal AF in the future. 12. 13. 14. 15. 16. 17. 18. REFERENCES 19. 1. Coumel P. Paroxysmal atrial fibrillation: a disorder of autonomic tone? Eur Heart J. Apr 1994;15 Suppl A:9-16. 2. Coumel P. Autonomic influences in atrial tachyarrhythmias. J Cardiovasc Electrophysiol. Oct 1996;7(10):999-1007. 3. Lombardi F, Malliani A, Pagani M, et al. Heart rate variability and its sympatho-vagal modulation. Cardiovasc Res. Aug 1996; 32(2):208-16. 4. Hulme EC, Birdsall NJ, Buckley NJ. Muscarinic receptor subtypes. Annu Rev Pharmacol Toxicol. 1990;30:633-73. 5. Felder CC. Muscarinic acetylcholine receptors: signal transduction through multiple effectors. Faseb J. May 1995;9(8): 619-25. 6. Caulfield MP, Birdsall NJ. International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors. Pharmacol Rev. Jun 1998;50(2):79-290. 7. Dhein S, van Koppen CJ, Brodde OE. Muscarinic receptors in the mammalian heart. Pharmacol Res. Sep 2001;44(3):161-82. 8. Burt JM, Spray DC. Single-channel events and gating behavior of the cardiac gap junction channel. Proc Natl Acad Sci U S A. May 1988;85(10):3431-4. 9. Takens-Kwak BR, Jongsma HJ. Cardiac gap junctions: three distinct single channel conductances and their modulation by phosphorylating treatments. Pflugers Arch. Nov 1992;422(2): 198-200. 10. Kwak BR, Jongsma HJ. Regulation of cardiac gap junction channel permeability and conductance by several phosphoryActa Cardiol Sin 2007;23:1-12 20. 21. 22. 23. 24. 25. 26. 27. 28. 8 lating conditions. Mol Cell Biochem. Apr 12-26 1996;157(1-2): 93-9. DiFrancesco D, Tromba C. Inhibition of the hyperpolarizationactivated current (if) induced by acetylcholine in rabbit sino-atrial node myocytes. J Physiol. Nov 1988;405:477-91. DiFrancesco D, Tromba C. Muscarinic control of the hyperpolarization-activated current (if) in rabbit sino-atrial node myocytes. J Physiol. Nov 1988;405:493-510. DiFrancesco D, Tortora P. Direct activation of cardiac pacemaker channels by intracellular cyclic AMP. Nature. May 9 1991; 351(6322):145-7. Yatani A, Okabe K, Codina J, et al. Heart rate regulation by G proteins acting on the cardiac pacemaker channel. Science. Sep 7 1990;249(4973):1163-66. Kubo Y, Reuveny E, Slesinger PA, et al. Primary structure and functional expression of a rat G-protein-coupled muscarinic potassium channel. Nature. Aug 26 1993;364(6440):802-6. Kurachi Y, Tung RT, Ito H, et al. G protein activation of cardiac muscarinic K+ channels. Prog Neurobiol. Sep 1992;39(3):22946. Yamada M, Inanobe A, Kurachi Y. G protein regulation of potassium ion channels. Pharmacol Rev. Dec 1998;50(4):723-60. Fischmeister R, Hartzell HC. Mechanism of action of acetylcholine on calcium current in single cells from frog ventricle. J Physiol. Jul 1986;376:183-202. Iijima T, Irisawa H, Kameyama M. Membrane currents and their modification by acetylcholine in isolated single atrial cells of the guinea-pig. J Physiol. Feb 1985;359:485-501. Sakai R, Shen JB, Pappano AJ. Elevated cAMP suppresses muscarinic inhibition of L-type calcium current in guinea pig ventricular myocytes. J Cardiovasc Pharmacol. Aug 1999;34(2): 304-15. Gupta RC, Neumann J, Boknik P, et al. M2-specific muscarinic cholinergic receptor-mediated inhibition of cardiac regulatory protein phosphorylation. Am J Physiol. Mar 1994;266(3 Pt 2): H1138-44. Harvey RD, Hume JR. Autonomic regulation of delayed rectifier K+ current in mammalian heart involves G proteins. Am J Physiol. Sep 1989;257(3 Pt 2):H818-23. Matsumoto K, Pappano AJ. Sodium-dependent membrane current induced by carbachol in single guinea-pig ventricular myocytes. J Physiol. Aug 1989;415:487-502. Harvey RD, Hume JR. Autonomic regulation of a chloride current in heart. Science. May 26 1989;244(4907):983-5. Ninomiya I. Direct evidence of nonuniform distribution of vagal effects on dog atria. Circ Res. Sep 1966;19(3):576-83. Alessi R, Nusynowitz M, Abildskov JA, et al. Nonuniform distribution of vagal effects on the atrial refractory period. Am J Physiol. Aug 1958;194(2):406-10. Liu L, Nattel S. Differing sympathetic and vagal effects on atrial fibrillation in dogs: role of refractoriness heterogeneity. Am J Physiol. Aug 1997;273(2 Pt 2):H805-16. Zipes DP, Mihalick MJ, Robbins GT. Effects of selective vagal Vagal Atrial Fibrillation 29. 30. 31. 32. 33. 34. 35. 36. 37. 38. 39. 40. 41. 42. 43. and stellate ganglion stimulation of atrial refractoriness. Cardiovasc Res. Sep 1974;8(5):647-55. Wang Z, Page P, Nattel S. Mechanism of flecainide’s antiarrhythmic action in experimental atrial fibrillation. Circ Res. Aug 1992;71(2):271-87. Moe GK, Rheinboldt WC, Abildskov JA. A Computer Model Of Atrial Fibrillation. Am Heart J. Feb 1964;67:200-20. Wang J, Liu L, Feng J, et al. Regional and functional factors determining induction and maintenance of atrial fibrillation in dogs. Am J Physiol. Jul 1996;271(1 Pt 2):H148-58. Kneller J, Zou R, Vigmond EJ, et al. Cholinergic atrial fibrillation in a computer model of a two-dimensional sheet of canine atrial cells with realistic ionic properties. Circ Res. May 17 2002; 90(9):E73-87. Hoover DB, Ganote CE, Ferguson SM, et al. Localization of cholinergic innervation in guinea pig heart by immunohistochemistry for high-affinity choline transporters. Cardiovasc Res. Apr 1 2004;62(1):112-21. Mabe AM, Hoard JL, Duffourc MM, et al. Localization of cholinergic innervation and neurturin receptors in adult mouse heart and expression of the neurturin gene. Cell Tissue Res. May 12 2006. Lomax AE, Rose RA, Giles WR. Electrophysiological evidence for a gradient of G protein-gated K+ current in adult mouse atria. Br J Pharmacol. Oct 2003;140(3):576-84. Huang CX, Zhao QY, Liang JJ, et al. Differential densities of muscarinic acetylcholine receptor and I(K,ACh) in canine supraventricular tissues and the effect of amiodarone on cholinergic atrial fibrillation and I(K,ACh). Cardiology. 2006;106(1):36-43. Sarmast F, Kolli A, Zaitsev A, et al. Cholinergic atrial fibrillation: I(K,ACh) gradients determine unequal left/right atrial frequencies and rotor dynamics. Cardiovasc Res. Oct 1 2003;59(4): 863-73. Sharifov OF, Zaitsev AV, Rosenshtraukh LV, et al. Spatial distribution and frequency dependence of arrhythmogenic vagal effects in canine atria. J Cardiovasc Electrophysiol. Sep 2000; 11(9):1029-42. Vigmond EJ, Tsoi V, Kuo S, et al. The effect of vagally induced dispersion of action potential duration on atrial arrhythmogenesis. Heart Rhythm. Sep 2004;1(3):334-44. Schuessler RB, Grayson TM, Bromberg BI, et al. Cholinergically mediated tachyarrhythmias induced by a single extrastimulus in the isolated canine right atrium. Circ Res. Nov 1992;71(5): 1254-67. Schuessler RB, Rosenshtraukh LV, Boineau JP, et al. Spontaneous tachyarrhythmias after cholinergic suppression in the isolated perfused canine right atrium. Circ Res. Oct 1991;69(4):1075-87. Comtois P, Kneller J, Nattel S. Of circles and spirals: bridging the gap between the leading circle and spiral wave concepts of cardiac reentry. Europace. Sep 2005;7 Suppl 2:10-20. Kovoor P, Wickman K, Maguire CT, et al. Evaluation of the role of I(KACh) in atrial fibrillation using a mouse knockout model. J Am Coll Cardiol. Jun 15 2001;37(8):2136-43. 44. Sharifov OF, Fedorov VV, Beloshapko GG, et al. Roles of adrenergic and cholinergic stimulation in spontaneous atrial fibrillation in dogs. J Am Coll Cardiol. Feb 4 2004;43(3):483-90. 45. Hashimoto K, Chiba S, Tanaka S, et al. Adrenergic mechanism participating in induction of atrial fibrillation by ACh. Am J Physiol. Nov 1968;215(5):1183-91. 46. Bettoni M, Zimmermann M. Autonomic tone variations before the onset of paroxysmal atrial fibrillation. Circulation. Jun 11 2002;105(23):2753-9. 47. Haissaguerre M, Jais P, Shah DC, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med. Sep 3 1998;339(10):659-66. 48. Chen YJ, Chen SA, Chang MS, et al. Arrhythmogenic activity of cardiac muscle in pulmonary veins of the dog: implication for the genesis of atrial fibrillation. Cardiovasc Res. Nov 2000;48(2): 265-73. 49. Cha TJ, Ehrlich JR, Zhang L, et al. Atrial tachycardia remodeling of pulmonary vein cardiomyocytes: comparison with left atrium and potential relation to arrhythmogenesis. Circulation. Feb 15 2005;111(6):728-35. 50. Schauerte P, Scherlag BJ, Patterson E, et al. Focal atrial fibrillation: experimental evidence for a pathophysiologic role of the autonomic nervous system. J Cardiovasc Electrophysiol. May 2001;12(5):592-9. 51. Patterson E, Po SS, Scherlag BJ, et al. Triggered firing in pulmonary veins initiated by in vitro autonomic nerve stimulation. Heart Rhythm. Jun 2005;2(6):624-31. 52. Patterson E, Yu X, Huang S, et al. Suppression of autonomicmediated triggered firing in pulmonary vein preparations, 24 hours postcoronary artery ligation in dogs. J Cardiovasc Electrophysiol. Jul 2006;17(7):763-70. 53. Takahashi Y, Jais P, Hocini M, et al. Shortening of fibrillatory cycle length in the pulmonary vein during vagal excitation. J Am Coll Cardiol. Feb 21 2006;47(4):774-80. 54. Scherlag BJ, Yamanashi W, Patel U, et al. Autonomically induced conversion of pulmonary vein focal firing into atrial fibrillation. J Am Coll Cardiol. Jun 7 2005;45(11):1878-86. 55. Zimmermann M, Kalusche D. Fluctuation in autonomic tone is a major determinant of sustained atrial arrhythmias in patients with focal ectopy originating from the pulmonary veins. J Cardiovasc Electrophysiol. Mar 2001;12(3):285-91. 56. Patterson E, Lazzara R, Szabo B, et al. Sodium-calcium exchange initiated by the Ca2+ transient: an arrhythmia trigger within pulmonary veins. J Am Coll Cardiol. Mar 21 2006;47(6):1196206. 57. Tai CT, Chiou CW, Wen ZC, et al. Effect of phenylephrine on focal atrial fibrillation originating in the pulmonary veins and superior vena cava. J Am Coll Cardiol. Sep 2000;36(3):788-93. 58. Oral H, Chugh A, Scharf C, et al. Pulmonary vein isolation for vagotonic, adrenergic, and random episodes of paroxysmal atrial fibrillation. J Cardiovasc Electrophysiol. Apr 2004;15(4):402-6. 59. Blaauw Y, Tieleman RG, Brouwer J, et al. Tachycardia induced electrical remodeling of the atria and the autonomic nervous 9 Acta Cardiol Sin 2007;23:1-12 Yung-Hsin Yeh et al. 60. 61. 62. 63. 64. 65. 66. 67. 68. 69. 70. 71. 72. system in goats. Pacing Clin Electrophysiol. Nov 1999;22(11): 1656-67. Dobrev D, Graf E, Wettwer E, et al. Molecular basis of downregulation of G-protein-coupled inward rectifying K(+) current (I(K,ACh) in chronic human atrial fibrillation: decrease in GIRK4 mRNA correlates with reduced I(K,ACh) and muscarinic receptor-mediated shortening of action potentials. Circulation. Nov 20 2001;104(21):2551-7. Shi H, Wang H, Li D, et al. Differential alterations of receptor densities of three muscarinic acetylcholine receptor subtypes and current densities of the corresponding K+ channels in canine atria with atrial fibrillation induced by experimental congestive heart failure. Cell Physiol Biochem. 2004;14(1-2):31-40. Brundel BJ, Van Gelder IC, Henning RH, et al. Alterations in potassium channel gene expression in atria of patients with persistent and paroxysmal atrial fibrillation: differential regulation of protein and mRNA levels for K+ channels. J Am Coll Cardiol. Mar 1 2001;37(3):926-32. Gonzalez RA, Campos EO, Karmelic C, et al. Acetylcholinesterase changes in hearts with sinus rhythm and atrial fibrillation. Gen Pharmacol. Jan 1993;24(1):111-4. Ehrlich JR, Cha TJ, Zhang L, et al. Characterization of a hyperpolarization-activated time-dependent potassium current in canine cardiomyocytes from pulmonary vein myocardial sleeves and left atrium. J Physiol. Jun 1 2004;557(Pt 2):583-97. Dobrev D, Friedrich A, Voigt N, et al. The G protein-gated potassium current I(K,ACh) is constitutively active in patients with chronic atrial fibrillation. Circulation. Dec 13 2005;112(24): 3697-706. Cha TJ, Ehrlich JR, Chartier D, et al. Kir3-based inward rectifier potassium current: potential role in atrial tachycardia remodeling effects on atrial repolarization and arrhythmias. Circulation. Apr 11 2006;113(14):1730-7. Wallukat G, Nissen E, Morwinski R, et al. Autoantibodies against the beta- and muscarinic receptors in cardiomyopathy. Herz. May 2000;25(3):261-6. Baba A, Yoshikawa T, Fukuda Y, et al. Autoantibodies against M2-muscarinic acetylcholine receptors: new upstream targets in atrial fibrillation in patients with dilated cardiomyopathy. Eur Heart J. Jul 2004;25(13):1108-15. van den Berg MP, Hassink RJ, Balje-Volkers C, et al. Role of the autonomic nervous system in vagal atrial fibrillation. Heart. Mar 2003;89(3):333-5. Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Circulation. Mar 1 1996;93(5):1043-65. Andresen D, Bruggemann T. Heart rate variability preceding onset of atrial fibrillation. J Cardiovasc Electrophysiol. Aug 1998;9(8 Suppl):S26-9. Fioranelli M, Piccoli M, Mileto GM, et al. Analysis of heart rate variability five minutes before the onset of paroxysmal atrial fibrillation. Pacing Clin Electrophysiol. May 1999;22(5):743-9. Acta Cardiol Sin 2007;23:1-12 73. Herweg B, Dalal P, Nagy B, et al. Power spectral analysis of heart period variability of preceding sinus rhythm before initiation of paroxysmal atrial fibrillation. Am J Cardiol. Oct 1 1998;82(7): 869-74. 74. Coccagna G, Capucci A, Bauleo S, et al. Paroxysmal atrial fibrillation in sleep. Sleep. Jun 1997;20(6):396-8. 75. Tomita T, Takei M, Saikawa Y, et al. Role of autonomic tone in the initiation and termination of paroxysmal atrial fibrillation in patients without structural heart disease. J Cardiovasc Electrophysiol. Jun 2003;14(6):559-64. 76. Roark SF, McCarthy EA, Lee KL, et al. Observations on the occurrence of atrial fibrillation in paroxysmal supraventricular tachycardia. Am J Cardiol. Mar 1 1986;57(8):571-5. 77. Chen YJ, Chen SA, Tai CT, et al. Role of atrial electrophysiology and autonomic nervous system in patients with supraventricular tachycardia and paroxysmal atrial fibrillation. J Am Coll Cardiol. Sep 1998;32(3):732-8. 78. van den Berg MP, Hassink RJ, Tuinenburg AE, et al. Quality of life in patients with paroxysmal atrial fibrillation and its predictors: importance of the autonomic nervous system. Eur Heart J. Feb 2001;22(3):247-53. 79. Nattel S, Opie LH. Controversies in atrial fibrillation. Lancet. Jan 21 2006;367(9506):262-72. 80. Fuster V, Ryden LE, Asinger RW, et al. ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the North American Society of Pacing and Electrophysiology. Circulation. Oct 23 2001;104(17):2118-50. 81. van den Berg MP, Haaksma J, Brouwer J, et al. Analysis of heart rate variability in a patient with paroxysmal atrial fibrillation. Eur Heart J. Dec 1995;16(12):2011-2. 82. Coumel P, Thomas O, Leenhardt A. Drug therapy for prevention of atrial fibrillation. Am J Cardiol. Jan 25 1996;77(3):3A-9A. 83. Razavi M, Zhang S, Yang D, et al. Effects of pulmonary vein ablation on regional atrial vagal innervation and vulnerability to atrial fibrillation in dogs. J Cardiovasc Electrophysiol. Aug 2005;16(8):879-84. 84. Pappone C, Santinelli V, Manguso F, et al. Pulmonary vein denervation enhances long-term benefit after circumferential ablation for paroxysmal atrial fibrillation. Circulation. Jan 27 2004;109(3):327-34. 85. Scherlag BJ, Nakagawa H, Jackman WM, et al. Electrical stimulation to identify neural elements on the heart: their role in atrial fibrillation. J Interv Card Electrophysiol. Aug 2005;13 Suppl 1:37-42. 86. Tan AY, Li H, Wachsmann-Hogiu S, et al. Autonomic innervation and segmental muscular disconnections at the human pulmonary vein-atrial junction: implications for catheter ablation of atrial10 Vagal Atrial Fibrillation 87. 88. 89. 90. 91. pulmonary vein junction. J Am Coll Cardiol. Jul 4 2006;48(1): 132-43. Chiou CW, Zipes DP. Selective vagal denervation of the atria eliminates heart rate variability and baroreflex sensitivity while preserving ventricular innervation. Circulation. Jul 28 1998; 98(4):360-8. Chiou CW, Eble JN, Zipes DP. Efferent vagal innervation of the canine atria and sinus and atrioventricular nodes. The third fat pad. Circulation. Jun 3 1997;95(11):2573-84. Chevalier P, Obadia JF, Timour Q, et al. Thoracoscopic epicardial radiofrequency ablation for vagal atrial fibrillation in dogs. Pacing Clin Electrophysiol. Jun 1999;22(6 Pt 1):880-6. Melo J, Voigt P, Sonmez B, et al. Ventral cardiac denervation reduces the incidence of atrial fibrillation after coronary artery bypass grafting. J Thorac Cardiovasc Surg. Feb 2004;127(2): 511-6. Alex J, Guvendik L. Evaluation of ventral cardiac denervation as 92. 93. 94. 95. 11 a prophylaxis against atrial fibrillation after coronary artery bypass grafting. Ann Thorac Surg. Feb 2005;79(2):517-20. Cummings JE, Gill I, Akhrass R, et al. Preservation of the anterior fat pad paradoxically decreases the incidence of postoperative atrial fibrillation in humans. J Am Coll Cardiol. Mar 17 2004; 43(6):994-1000. Hirose M, Leatmanoratn Z, Laurita KR, et al. Partial vagal denervation increases vulnerability to vagally induced atrial fibrillation. J Cardiovasc Electrophysiol. Dec 2002;13(12): 1272-9. Oh S, Zhang Y, Bibevski S, et al. Vagal denervation and atrial fibrillation inducibility: epicardial fat pad ablation does not have long-term effects. Heart Rhythm. Jun 2006;3(6):701-8. Hashimoto N, Yamashita T, Tsuruzoe N. Tertiapin, a selective IK(ACh) blocker, terminates atrial fibrillation with selective atrial effective refractory period prolongation. Pharmacol Res. Apr 1 2006. Acta Cardiol Sin 2007;23:1-12 Review Acta Cardiol Sin 2007;23:1−12 迷走神經性心房顫動 葉勇信 1,2,4 Kristina Lemola1,2 Stanley Nattel1,2,3 Department of Medicine and Research Center, Montreal Heart Institute, Quebec, Canada1 Department of Medicine, University of Montreal, Quebec, Canada2 Department of Pharmacology McGill University, Quebec, Canada3 基隆市 長庚紀念醫院 心臟內科4 自主神經系統在於引起心房顫動扮演重要的角色,迷走神經性心房顫動係指副交感神經興 奮所引起的心房顫動。其作用機轉主要是經由活化乙醯膽鹼鉀離子通道 (IKACh),在心房造 成不均勻地不反應期與動作電位縮短,形成再進入迴路 (reentry) 因而誘發心房顫動。交 感神經興奮會使迷走神經性心房顫動更容易發生。副交感神經興奮會使肺靜脈異常放電更 容易發生,因此肺靜脈異常放電也可能是引起迷走神經性心房顫動的重要原因。心臟本身 疾病會改變迷走神經對於心房細胞的正常作用,可能也是引起心房顫動的原因。臨床的診 斷仍主要有賴於詳細病史詢問,去迷走神經 (vagal denervation) 是否能治療迷走神經性心 房顫動仍有爭議,特異性乙醯膽鹼鉀離子通道阻斷劑未來可能是治療方式的選擇之一。 關鍵詞:迷走神經性心房顫動、乙醯膽鹼、蕈毒鹼接受器、肺靜脈、去迷走神經化。 12